CANDICE BOLLING: Open Payments
NPI 1477736684 · SAINT PAUL, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$821 in 57 payments from 14 companies in 2025. Trend: 2023 $290 · 2024 $736 · 2025 $821
Food & beverage: $821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $156 |
| Novo Nordisk Inc | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| Abbott Laboratories | 4 | $74 |
| GlaxoSmithKline, LLC. | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $35 |
Products named: VRAYLAR, REXULTI, FREESTYLE LIBRE 3, TRELEGY ELLIPTA, CAPLYTA, HETLIOZ, Auvelity, Ozempic.
Industry payments across VA — which companies pay providers there.
